These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 9827420)

  • 1. Use of formoterol dry powder administered for three months via a single-dose inhaler in 1,380 asthmatic patients.
    Clauzel AM; Molimard M; Le Gros V; Lepère E; Febvre N; Michel FB
    J Investig Allergol Clin Immunol; 1998; 8(5):265-70. PubMed ID: 9827420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study.
    Busse W; Levine B; Andriano K; Lavecchia C; Yegen U
    Clin Ther; 2004 Oct; 26(10):1587-98. PubMed ID: 15598475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparable efficacy and tolerability of formoterol (Foradil) administered via a novel multi-dose dry powder inhaler (Certihaler) or the Aerolizer dry powder inhaler in patients with persistent asthma.
    Dahl R; Creemers JP; Van Noord J; Sips A; Della Cioppa G; Thomson M; Andriano K; Kottakis J; Fashola T
    Respiration; 2004; 71(2):126-33. PubMed ID: 15031566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
    Dusser D; Vicaut E; Lefrançois G;
    Respiration; 2005; 72 Suppl 1():20-7. PubMed ID: 15915009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma.
    Scicchitano R; Aalbers R; Ukena D; Manjra A; Fouquert L; Centanni S; Boulet LP; Naya IP; Hultquist C
    Curr Med Res Opin; 2004 Sep; 20(9):1403-18. PubMed ID: 15383189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similar efficacy following four weeks treatment of asthmatics with formoterol 12 micrograms b.d. delivered by two different dry powder inhalers: differences in inhaler handling.
    Eliraz A; Ramirez-Rivera A; Ferranti P; Holzer R; García JM; Turcotte C; Rapatz G; Pfister P; Overend T; Kottakis J
    Int J Clin Pract; 2001 Apr; 55(3):164-70. PubMed ID: 11351769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bronchial asthma treated with long-acting beta 2 agonist. Comparison between formoterol (12 mu/g) inhaled twice daily and salbutamol (200 mu/g) inhaled 4 times daily].
    Sprogøe-Jakobsen U; Viktrup L; Davidsen O; Viskum K
    Ugeskr Laeger; 1992 Nov; 154(47):3325-8. PubMed ID: 1361083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of formoterol delivered via a new multidose dry powder inhaler (Certihaler) in adolescents and adults with persistent asthma.
    LaForce C; Prenner BM; Andriano K; Lavecchia C; Yegen U
    J Asthma; 2005 Mar; 42(2):101-6. PubMed ID: 15871441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of persistent asthma with Symbicort (budesonide/formoterol inhalation aerosol): an inhaled corticosteroid and long-acting beta2-adrenergic agonist in one pressurized metered-dose inhaler.
    Berger WE; Noonan MJ
    J Asthma; 2010 May; 47(4):447-59. PubMed ID: 20528601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma.
    Corren J; Mansfield LE; Pertseva T; Blahzko V; Kaiser K
    Respir Med; 2013 Feb; 107(2):180-95. PubMed ID: 23273405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Changes in specific airway resistance after powder inhalation of formoterol or salmeterol in moderate bronchial asthma].
    Sill V; Bartuschka B; Villiger B; Ortland C; Domej W
    Pneumologie; 1999 Jan; 53(1):4-9. PubMed ID: 10091511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma.
    Tal A; Simon G; Vermeulen JH; Petru V; Cobos N; Everard ML; de Boeck K
    Pediatr Pulmonol; 2002 Nov; 34(5):342-50. PubMed ID: 12357478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
    FitzGerald JM; Boulet LP; Follows RM
    Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lung function and asthma control with beclomethasone and formoterol in a single inhaler.
    Huchon G; Magnussen H; Chuchalin A; Dymek L; Gonod FB; Bousquet J
    Respir Med; 2009 Jan; 103(1):41-9. PubMed ID: 18977646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 12-week, multicenter, randomized, partially blinded, active-controlled, parallel-group study of budesonide inhalation suspension in adolescents and adults with moderate to severe persistent asthma previously receiving inhaled corticosteroids with a metered-dose or dry powder inhaler.
    Murphy K; Noonan M; Silkoff PE; Uryniak T
    Clin Ther; 2007 Jun; 29(6):1013-26. PubMed ID: 17692718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhalation devices for long-acting beta2-agonists: efficiency and ease of use of dry powder formoterol inhalers for use by patients with asthma and COPD.
    Molimard M; Till D; Stenglein S; Singh D; Krummen M
    Curr Med Res Opin; 2007 Oct; 23(10):2405-13. PubMed ID: 20350055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluticasone/formoterol combination therapy versus budesonide/formoterol for the treatment of asthma: a randomized, controlled, non-inferiority trial of efficacy and safety.
    Bodzenta-Lukaszyk A; Buhl R; Balint B; Lomax M; Spooner K; Dissanayake S
    J Asthma; 2012 Dec; 49(10):1060-70. PubMed ID: 23102189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of asthma therapy by a novel formoterol multidose dry powder inhaler.
    Moeller M; Grimmbacher S; Munzel U
    Arzneimittelforschung; 2008; 58(4):168-73. PubMed ID: 18540478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-daily dosing with budesonide/formoterol compared with twice-daily budesonide/formoterol and once-daily budesonide in adults with mild to moderate asthma.
    Kuna P; Creemers JP; Vondra V; Black PN; Lindqvist A; Nihlen U; Vogelmeier C
    Respir Med; 2006 Dec; 100(12):2151-9. PubMed ID: 16701989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of once-daily budesonide/formoterol pressurized metered-dose inhaler in adults and adolescents with asthma previously stable with twice-daily budesonide/ formoterol dosing.
    Kerwin EM; Oppenheimer JJ; LaForce C; Parasuraman B; Miller CJ; O'Dowd L; Goldman M
    Ann Allergy Asthma Immunol; 2009 Jul; 103(1):62-72. PubMed ID: 19663129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.